Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients

European Journal of Medical Research

Volumn 19, Issue 1, 2014, Pages

  Xu, Chunhua ^a   Yu, Like ^a   Zhan, Ping ^a   Zhang, Yu ^a  

^a NANJING CHEST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; OVERALL SURVIVAL; PLEURA EFFUSION; PLEURA FLUID; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SURVIVAL TIME; AGED; BIOSYNTHESIS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901976104     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-19-23     Document Type: Article

References (30)

1. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. Kasahara K, Shibata K, Shintani H, Iwasa K, Sone T, Kimura H, Nobata K, Hirose T, Yoshimi Y, Katayama N, Ishiura Y, Kita T, Nishi K, Nakatsumi Y, Ryoma Y, Fujimura M, Nakao S, Anticancer Res 2006 26 1495 1499 16619563
2. Application of MMP-7 and MMP-10 in assisting the diagnosis of malignant pleural effusion. Cheng D, Liang B, Li YH, Asian Pac J Cancer Prev 2012 13 505 509 10.7314/APJCP.2012.13.2.505 22524815
3. Diagnostic significance of interferon-γ in tuberculous pleural effusions. Aoe K, Hiraki A, Murakami T, Eda R, Maeda T, Sugi K, Takeyama H, Chest 2003 123 740 744 10.1378/chest.123.3.740 12628872 (Pubitemid 36315487)
4. Relative abundance and patterns of correlation among six cytokines in pleural fluid measured by cytometric bead array. Aoe K, Hiraki A, Murakami T, Murakami K, Makihata K, Takao K, Eda R, Maeda T, Sugi K, Darzynkiewicz Z, Takeyama H, Int J Mol Med 2003 12 193 198 12851716
5. Simultaneous measurement of T-helper 1 cytokines in tuberculous pleural effusion. Hiraki A, Aoe K, Matsuo K, Murakami K, Murakami T, Onoda T, Sugi K, Takeyama H, Eda R, Int J Tuberc Lung Dis 2003 7 1172 1177 14677892 (Pubitemid 38004741)
6. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Hiraki A, Aoe K, Eda R, Maeda T, Murakami T, Sugi K, Takeyama H, Chest 2004 125 987 989 10.1378/chest.125.3.987 15006958 (Pubitemid 38367290)
7. Diagnostic molecular biomarkers for malignant pleural effusions. Sriram KB, Relan V, Clarke BE, Duhig EE, Yang IA, Bowman RV, Lee YC, Fong KM, Future Oncol 2011 7 737 752 10.2217/fon.11.45 21675837
8. Diagnosis and management of malignant pleural effusions. Heffner JE, Respirology 2008 13 5 20 18197908
9. Diagnostic value of CA 549 in pleural fluid: comparison with CEA, CA 15.3 and CA 72.4. Villena V, López-Encuentra A, Echave-Sustaeta J, Martín-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J, Lung Cancer 2003 40 289 294 10.1016/S0169-5002(03)00120-X 12781427 (Pubitemid 36627708)
10. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F, Chest 2004 126 1757 1763 10.1378/chest.126.6.1757 15596670 (Pubitemid 39643976)
11. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients. Aoe K, Hiraki A, Yamazaki K, Nakamura Y, Murakami T, Maeda T, Nishimura M, Sugi K, Ueoka H, Int J Oncol 2006 29 65 72 16773186
12. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion: a pilot study. Su WC, Lai WW, Chen HH, Hsiue TR, Chen CW, Huang WT, Chen TY, Tsao CJ, Wang NS, Oncology 2003 64 18 24 10.1159/000066516 12457027 (Pubitemid 35477950)
13. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW, Lung Cancer 2009 65 371 376 10.1016/j.lungcan.2008.12.007 19157636
14. Crucial role of CD4 + CD25 + FOXP3+ T regulatory cell, interferon-γ and interleukin-16 in malignant and tuberculous pleural effusions. Ibrahim L, Salah M, Abd El Rahman A, Zeidan A, Ragb M, Immunol Invest 2013 42 122 136 10.3109/08820139.2012.736116 23252864
15. + T cells in malignant pleural effusion. Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin JB, Tao XN, Shi HZ, J Immunol 2010 185 6348 6354 10.4049/jimmunol.1001728 20952674
16. T lymphocytes in pleural effusion. Yang HB, Shi HZ, Chin Med J (Engl) 2008 121 579 580 18466674
17. + regulatory T lymphocytes in tuberculous pleural effusion. Qin XJ, Shi HZ, Liang QL, Huang LY, Yang HB, Chin Med J (Engl) 2008 121 581 586 18466675
18. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H, J Exp Med 2009 206 1457 1464 10.1084/jem.20090207 19564351
19. reg skewing. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG, Clin Cancer Res 2008 14 3254 3261 10.1158/1078-0432.CCR-07-5164 18519750
20. + IL-17-producing T cells in ovarian cancer. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF, Proc Natl Acad Sci U S A 2008 105 15505 15510 10.1073/pnas.0710686105 18832156
21. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W, Blood 2009 114 1141 1149 10.1182/blood-2009- 03-208249 19470694
22. Increased frequencies of T helper type 17 cells in tuberculous pleural effusion. Wang T, Lv M, Qian Q, Nie Y, Yu L, Hou Y, Tuberculosis (Edinb) 2011 91 231 237 10.1016/j.tube.2011.02.002 21371943
23. + regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, Qin SM, Xin JB, Shi HZ, Respir Res 2011 12 77 10.1186/1465-9921-12-77 21663645
24. H17 cells in development: an updated view of their molecular identity and genetic programming. Dong C, Nat Rev Immunol 2008 8 337 348 10.1038/nri2295 18408735 (Pubitemid 351595217)
25. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ, Prostate 2003 56 171 182 10.1002/pros.10238 12772186 (Pubitemid 36918167)
26. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, Seikour A, Charachon A, Karoui M, Leroy K, Farcet JP, Sobhani I, Gut 2008 57 772 779 10.1136/gut.2007.123794 17965063 (Pubitemid 351716970)
27. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L, J Hepatol 2009 50 980 989 10.1016/j.jhep.2008.12.033 19329213
28. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM, Jackson AM, Breast Cancer Res 2008 10 95 10.1186/bcr2195 19014637
29. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z, Lung Cancer 2010 69 348 354 10.1016/j.lungcan.2009.11.013 20022135
30. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E, Blood 2002 99 2114 2121 10.1182/blood.V99.6.2114 11877287 (Pubitemid 34525496)